|
US11771697B2
(en)
*
|
2018-04-30 |
2023-10-03 |
Dana-Farber Cancer Institute, Inc. |
Small molecule degraders of polybromo-1 (PBRM1)
|
|
CN113874016A
(zh)
|
2019-01-29 |
2021-12-31 |
福宏治疗公司 |
化合物及其用途
|
|
AR119731A1
(es)
|
2019-05-17 |
2022-01-05 |
Novartis Ag |
Inhibidores del inflamasoma nlrp3
|
|
JP2022533260A
(ja)
*
|
2019-05-24 |
2022-07-21 |
バイオセリックス， インコーポレイテッド |
タンパク質を標的とする化合物及びその医薬組成物並びにそれらの治療的応用
|
|
WO2020251972A1
(en)
|
2019-06-10 |
2020-12-17 |
Kymera Therapeutics, Inc. |
Smarca degraders and uses thereof
|
|
WO2021022163A2
(en)
|
2019-07-31 |
2021-02-04 |
Foghorn Therapeutics Inc. |
Compounds and uses thereof
|
|
PH12022550578A1
(en)
*
|
2019-09-12 |
2024-02-19 |
Aurigene Discovery Tech Ltd |
Method for identifying responders to smarca2/4 degraders
|
|
JP2023511471A
(ja)
*
|
2019-10-28 |
2023-03-20 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
二官能性化合物
|
|
JP2023511472A
(ja)
*
|
2019-10-29 |
2023-03-20 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
がんの治療のための二官能性化合物
|
|
CN110790746B
(zh)
*
|
2019-11-18 |
2020-10-30 |
南京恒通医药开发有限公司 |
一种利用微通道反应器连续化制备泊马度胺的合成工艺
|
|
EP4081308A4
(en)
*
|
2019-12-23 |
2024-01-24 |
Kymera Therapeutics, Inc. |
Smarca degraders and uses thereof
|
|
WO2021142247A1
(en)
|
2020-01-10 |
2021-07-15 |
Amgen Inc. |
Smarca2-vhl degraders
|
|
US12528825B2
(en)
|
2020-01-29 |
2026-01-20 |
Foghorn Therapeutics Inc. |
Compounds and uses thereof
|
|
EP4096651A4
(en)
|
2020-01-29 |
2024-01-24 |
Foghorn Therapeutics Inc. |
COMPOUNDS AND THEIR USES
|
|
US12599671B2
(en)
|
2020-02-12 |
2026-04-14 |
Dana-Farber Cancer Institute, Inc. |
Compounds, compositions, and methods for protein degradation
|
|
WO2021207291A1
(en)
*
|
2020-04-06 |
2021-10-14 |
Foghorn Therapeutics Inc. |
Compounds and uses thereof
|
|
US11739101B2
(en)
|
2020-05-06 |
2023-08-29 |
Nurix Therapeutics, Inc. |
Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof
|
|
US11787800B2
(en)
|
2020-07-29 |
2023-10-17 |
Foghorn Therapeutics Inc. |
BRD9 degraders and uses thereof
|
|
US12570650B2
(en)
*
|
2020-08-04 |
2026-03-10 |
Aurigene Oncology Limited |
6-substituted pyridazine compounds as SMARCA2 and/or SMARCA4 degraders
|
|
WO2022099117A1
(en)
*
|
2020-11-06 |
2022-05-12 |
Prelude Therapeutics Incorporated |
Brm targeting compounds and associated methods of use
|
|
JP7723743B2
(ja)
*
|
2020-11-20 |
2025-08-14 |
フォグホーン セラピューティクス インコーポレイテッド |
化合物及びその使用
|
|
EP4259144A4
(en)
*
|
2020-12-09 |
2025-08-20 |
Kymera Therapeutics Inc |
SMARCA DEGRADING AGENTS AND THEIR USES
|
|
CN117337178A
(zh)
*
|
2021-05-10 |
2024-01-02 |
福宏治疗公司 |
化合物及其用途
|
|
KR20240004983A
(ko)
*
|
2021-05-10 |
2024-01-11 |
포그혼 쎄라퓨틱스 인크. |
화합물 및 이의 용도
|
|
US11767330B2
(en)
|
2021-07-06 |
2023-09-26 |
Foghorn Therapeutics Inc. |
Citrate salt, pharmaceutical compositions, and methods of making and using the same
|
|
CN115611881B
(zh)
*
|
2021-07-13 |
2024-09-20 |
复旦大学 |
一种合成新型vhl配体4-f-vh032的方法
|
|
KR20240046498A
(ko)
|
2021-08-09 |
2024-04-09 |
제넨테크, 인크. |
Brm의 조절에 사용하기 위한 페놀 유도체
|
|
US20250145609A1
(en)
*
|
2022-02-09 |
2025-05-08 |
Aurigene Oncology Limited |
3-substituted pyridazine compounds as smarca2 and/or smarca4 degraders
|
|
UY40374A
(es)
|
2022-08-03 |
2024-02-15 |
Novartis Ag |
Inhibidores de inflamasoma nlrp3
|
|
WO2024064328A1
(en)
|
2022-09-23 |
2024-03-28 |
Regents Of The University Of Michigan |
Compounds and compositions as smarca2/4 degraders and uses thereof
|
|
WO2024064358A1
(en)
|
2022-09-23 |
2024-03-28 |
Ifm Due, Inc. |
Compounds and compositions for treating conditions associated with sting activity
|
|
WO2024064316A1
(en)
|
2022-09-23 |
2024-03-28 |
Regents Of The University Of Michigan |
Compounds and compositions as smarca2/4 inhibitors and uses thereof
|
|
WO2024137742A1
(en)
|
2022-12-20 |
2024-06-27 |
Blueprint Medicines Corporation |
Compounds and compositions as fgfr3 degraders and uses thereof
|
|
PE20260307A1
(es)
|
2023-06-14 |
2026-02-11 |
Astrazeneca Ab |
Degradadores de smarca2 y usos de estos
|
|
PE20260301A1
(es)
|
2023-06-14 |
2026-02-10 |
Astrazeneca Ab |
Derivados de 3-[3-amino-6-(2-hidroxifenil)piridazin-4-il]-3,8-diazabiciclo[3.2.1]octano como protacs degradantes de smarca2 para el tratamiento del cancer
|
|
CN121816356A
(zh)
*
|
2023-07-28 |
2026-04-07 |
甘李药业股份有限公司 |
一种选择性降解smarca2/4的化合物及其应用
|
|
CN118406019B
(zh)
*
|
2024-07-02 |
2024-09-20 |
苏州源起材料科技有限公司 |
一种噻唑化合物生物医药砌块的合成方法
|
|
WO2026061475A1
(zh)
*
|
2024-09-19 |
2026-03-26 |
标新生物医药科技(上海)有限公司 |
含有芳基取代杂芳基的双功能蛋白降解剂及其应用
|